Mechanism Study of G Protein-coupled Receptor 81 in Multiple Organ Dysfunction of Heat Stroke

May 26, 2026 updated by: Second Affiliated Hospital of Wenzhou Medical University
Heat stroke is one of the common acute and critical conditions in the ICU, characterized by a high incidence and mortality rate, and there is still a lack of effective and precise treatment methods. The latest research indicates that G protein-coupled receptor 81 (GPR81), as an endogenous receptor of lactic acid, can regulate immune responses by up-regulating the expression of inflammatory factors and the chemotaxis of neutrophils, suggesting that the GPR81 receptor may play a potential key role in heat stroke. The investigators aim to reveal the position and key role of GPR81 in improving multiple organ dysfunction caused by heat stroke, and to clarify its specific molecular mechanism, with the goal of providing new ideas for the prevention and treatment of heat stroke based on lactate levels, a commonly used clinical indicator.

Study Overview

Status

Active, not recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Zhejiang
      • Wenzhou, Zhejiang, China, 325000
        • Second Affiliated Hospital of Wenzhou Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients who are diagnosed with heatstroke

Description

Inclusion Criteria:

  • 1) There was a clear history of high-temperature exposure before the onset of the disease; 2) Core body temperature ≥40℃ upon admission or within 2 hours of onset; 3) At least one abnormal symptom of the central nervous system occurs 4) Sign an informed consent form or have their legal representative agree to participate in the research.

Exclusion Criteria:

  • 1) Suffering from central nervous system diseases; 2) Long-term use of anticoagulants; 3) Those who refuse to participate or withdraw their informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
heatstroke group
heatstroke patient, no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The 28-day survival rate of patients with heat stroke
Time Frame: Survival status will be assessed over a period of up to 28 days, starting from the date of hospital admission.
For patients with heat stroke, if they die within 28 days, it indicates they are non-survivors; if they do not die within 28 days, it indicates they are survivors
Survival status will be assessed over a period of up to 28 days, starting from the date of hospital admission.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma lactate levels in patients with heat stroke
Time Frame: Plasma lactate levels will be measured at admission and then daily during the hospital stay, for a period of up to 28 days.
Collect the plasma lactic acid level each time when patients with heat stroke are hospitalized
Plasma lactate levels will be measured at admission and then daily during the hospital stay, for a period of up to 28 days.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Second Affiliated Hospital of Wenzhou Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

January 31, 2027

Study Registration Dates

First Submitted

January 5, 2026

First Submitted That Met QC Criteria

January 15, 2026

First Posted (Actual)

January 16, 2026

Study Record Updates

Last Update Posted (Actual)

May 29, 2026

Last Update Submitted That Met QC Criteria

May 26, 2026

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SAHoWMU-CR2025-03-136

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Study protocol and statistical analysis plan.

IPD Sharing Time Frame

Beginning 6 months after publication with no end date

IPD Sharing Access Criteria

Deidentifed participant data underlying the findings wil be made available upon reasonable request. proposls fordata acess should be directedto the corresponding author Shengwei Jin

IPD Sharing Supporting Information Type

  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heat Stroke

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe